Skip to main content
Fig. 3 | BMC Neuroscience

Fig. 3

From: Maternal diabetes-mediated RORA suppression contributes to gastrointestinal symptoms in autism-like mouse offspring

Fig. 3

RORA agonist and SOD mimetic reverse maternal diabetes-mediated pre-inflammatory cytokine release in PBMC. Dams were divided into the following treatment groups: control (CTL/VEH), diabetes (STZ/VEH), diabetes plus SOD mimetic MnTBAP (STZ/MnTBAP), or diabetes plus RORA agonist SR1078 (STZ/SR1078) during pregnancy, and the PBMC were isolated from male offspring for biomedical analysis. a mRNA levels of pre-inflammatory cytokines, n = 4. b IL-1β secretion, n = 9. c IL-6 secretion, n = 9. d MCP1 secretion, n = 9. e IL17A secretion, n = 9. f mRNA levels of RORA and target genes, n = 4. g ChIP analysis on the RORA promoter, n = 4. The one-way ANOVA analysis was performed to determine statistical significance of different groups. *P < 0.05, vs. CTL/VEH group; ¶P < 0.05, vs. STZ/VEH group. Data were expressed as mean ± SD

Back to article page

BMC Neuroscience

ISSN: 1471-2202

Contact us